Cambridge Healthtech Institute’s 3rd Annual

Gene Therapy CMC and Analytics

Regulation and Analysis of Vector-Based Gene Therapies

August 14-15, 2019

 

Gene therapy is an extremely promising technique for the treatment of incurable diseases such as cancer and genetic disorders such as hemophilia. However, the analysis, characterization and delivery of these unique products remain a key issue.

Cambridge Healthtech Institute’s Gene Therapy CMC and Analytics meeting uncovers the practical challenges facing vector-based gene therapy analytics, assay development, quality control, vector development and delivery.

Final Agenda

August 12-13 Recommended Training Seminar

TS4A: Intro to Gene Therapy and Viral Vectors

Wednesday, August 14

7:00 am Registration Open and Morning Coffee

REGULATORY EXPECTATIONS AND CMC STRATEGIES

8:05 Chairperson’s Remarks

Michael Kelly, PhD, Director, Asset Leadership, Gene Therapy, Biogen

8:15 KEYNOTE PRESENTATION: Regulation and Challenges in Developing Vector-Based Gene Therapies

Mo Heidaran, PhD, Vice President, Technical, PAREXEL Consulting, PAREXEL International

While it is assumed that regulatory approval often leads to commercial success, this may not become an overwhelming trend in the field of gene therapy. The major reasons for this disconnect will be discussed in my presentation but full understanding of how these products work (knowledge of the product) and how these products could be consistently manufactured must be an essential part of the product development cycle.

9:00 USP Standards Development Activities to Support Gene Therapies

Jim Richardson, PhD, Senior Science and Standards Liaison, Global Biologics, United States Pharmacopeia

Gene therapy offers tremendous promise to address human disease but their complexity and diversity present unique challenges. USP is engaging with stakeholders to identify and develop documentary and physical standards to support gene therapy. This presentation will provide an overview of general chapters <1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products, and <1047> Gene Therapy Products as well as an update on documentary and physical reference standards under development.

9:30 Developing CMC Strategies to Advance a Gene Therapy Pipeline

Rajiv Gangurde, PhD, Director, CMC Portfolio Management, Voyager Therapeutics

10:00 Coffee Break in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)

ANALYTICAL CONTROL STRATEGIES

10:45 Plasmid DNA Topology and Triple Transfection rAAV Production

Lawrence Thompson, PhD, Principal Scientist, Analytical Research & Development, BioTherapeutics Pharm Sciences, Pfizer

Current regulatory guidance suggests that some measure of plasmid DNA potency be captured in the analytical control strategy. For plasmid DNA used in triple transfection rAAV production, this can only be described as attributes of said plasmid that, when controlled, are able to produce rAAV of the appropriate quantity and quality. This presentation is a case study that will pressure test plasmid DNA topology as one of those attributes.

11:15 A Digestion-Free Method for Residual DNA Quantification in rAAV Vectors

Yu Wang, PhD, Scientist II, Analytical Development, Biogen

The existing methods for residual DNA quantification in rAAV require digestion of capsid proteins by proteinase. We have developed a digestion-free method that significantly simplifies sample preparation and shortens assay time. The method has been verified by qPCR, as well as the more recent ddPCR technology for quantification of residual host cell or plasmid DNA in varies of AAV serotypes.

11:45 Meaningful Analytics Data for Quick Decision Making in Development of Viral Vector-Based Therapies

Vanessa Carvalho, Senior Scientist, EM Services, Vironova

12:15 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:00 Session Break

ANALYTICAL STRATEGIES FOR VIRAL VECTORS

1:45 Chairperson’s Remarks

Xiaohui Lu, PhD, Director, Analytical Development, Ultragenyx Pharmaceutical

1:50 Strategies and Advances in AAV Vector Characterization: Product-Related Impurities

Christine Le Bec, PhD, Head, CMC Analytical, Technology Development, Genethon

Selected analytical assays were developed to assess the vector productivity, vector purity, biological activity/potency. The quantitative PCR (qPCR) is the current gold method of titrating AAV genomes. The Droplet Digital PCR (ddPCR), a new technology which has been designed for accurate DNA quantification, could improve titer determination. Comparison between these two methods will be discussed. The presentation will also cover methods to determine the ratio of full/empty viral capsids.

2:20 Comparative Studies on the Empty/Full AAV Capsid Using Multiple Analytical Methods

Dong Xu, PhD, Senior Scientist, Analytical Development, Biogen, Inc.

For AAV-delivered gene therapy, the percentage of full viral capsid is an important product quality that needs to be quantitatively characterized. We have used several analytical tools to investigate the ratio of empty to full capsid ratio, including HPLC, CE, AUC, PCR, TEM and Mass Spectrometry. The comparison of these results reveals to us the advantages and limitations of each method in industrial applications.

2:50 Bioassay Development for AAV Gene Therapy Products

Aisleen McColl-Carboni, PhD, Senior Scientist, Sanofi

Health authorities emphasize the importance of employing suitable dose-determining methods for gene therapy products. We will discuss the analysis and characterization methods employed to support gene therapy projects. This presentation spans method development through qualification, and illustrating the benefits of comparing platforms early in product development.

3:20 Development of a High-Content Imaging Potency Assay to Support a Manufacturing Platform

Anthony Leyme, PhD, Scientist II, Technical Development, Analytical Bioassay Development, Biogen

AAV-based vectors represent a new type of drugs being developed for gene delivery in different therapeutic areas. Biological assays are required to assess vector quality, biological activity and safety. Potency of the drug is the most critical quality attribute, it must be specific, quantitative, and ideally reflective of the mechanism of action. This presentation will focus on the development of a high-content imaging potency assay to support a manufacturing platform.

3:50 Refreshment Break in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)


4:45 Plenary Keynote Session View details

6:00 A Taste of New England Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)

7:00 End of Day

Thursday, August 15

8:00 am Registration Open and Morning Coffee

PRODUCT CHARACTERIZATION

8:25 Chairperson’s Remarks

Wei-Chiang Chen, PhD, Senior Scientist, Analytical, Solid Bioscience

8:30 Material Identity Testing for Manufacturing of Gene Therapy Products in an Academic Setting

Sebastiaan Van Zalen, PhD, Quality Manager, Clinical Vector Core, Children’s Hospital of Philadelphia

Identity testing of raw materials used for manufacturing of investigational gene therapy drugs poses several challenges. We will discuss which of the available techniques would be most suitable and what adaptations and methods can be developed to help identify these raw materials. We will also address how to comply with the increasing regulatory requirements in an academic setting in which the composition of the materials varies for each product lot.

9:00 An Approach to Developing Analytical Testing and Release Plans for AAV Gene Therapy Vectors

Elizabeth Higgins, PhD, Director, Analytical Sciences, Voyager Therapeutics, Inc.

A suite of analytical tests is critical to support product characterization, process development, stability and batch release of AAV gene-therapy products. The selection of assays is driven by the development stage of the program, the transgene and the manufacturing process. This presentation will describe the approach that Voyager has taken, including platform analytical methods to support multiple programs, leveraging assays used for therapeutic proteins and developing specific potency assays.

9:30 Sponsored Presentation (Opportunity Available)

10:00 Coffee Break in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)

ADVANCING ANALYTICAL METHODS

10:45 Quality Control and Analysis of Gene Therapies

Mark Galbraith, PhD, Head, Quality Control and Analytical Sciences, Spark Therapeutics

11:15 Improving Viral Manufacture through Advanced Process Analytical Technologies

Damian Marshall, PhD, Director, New Technologies, Cell & Gene Therapy Catapult UK

Developing manufacturing strategies which can service the growing global demand for high quality viral vectors is a significant challenge. This is creating an industry pull for more advanced process control and smarter manufacturing technologies. This presentation will present new data on the application of optical biosensors for in-process monitoring and look at the potential role that artificial intelligence could play in supporting future viral vector production.

11:45 Panel Discussion: Analytical Strategies for Gene Therapies

Moderator:

Wei-Chiang Chen, PhD, Senior Scientist, Analytical, Solid Bioscience

Panelists:

Xiaohui Lu, PhD, Director, AAV, Production, CRISPR Therapeutics

Bo Yan, PhD, Senior Scientist, Analytical Development, Beam Therapeutics

Damian Marshall, PhD, Director, New Technologies, Cell & Gene Therapy Catapult UK

Xiaohui Lu, PhD, Director, Analytical Development, Ultragenyx Pharmaceutical

  • What are the best tools to characterize AAV and lenti-based gene therapies – MS, NMR, HPLC
  • Assay and potency assay development for gene therapies
  • In vivo tests, molecular tests and profiling
  • Stability indicating assays

12:15 pm Enjoy Lunch on Your Own

1:15 Refreshment Break in the Exhibit Hall with Last Chance for Poster Viewing (Sponsorship Opportunity Available)

1:55 End of Conference

* The program is subject to change without notice, due to unforeseen reason.